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Abstract 
 
 
 
COMPARING TOOTH ENAMEL DISTURBANCES IN A PEDIATRIC POPULATION 
THAT HAD RECEIVED PRIOR CHEMOTHERAPY TREATMENT TO AGE-MATCHED 
CONTROLS FROM THE VIRGINIA COMMONWEALTH UNIVERSITY PEDIATRIC 
DENTISTRY CLINIC. 
 
By Marcela R. Mujica, DMD 
 
A thesis submitted in partial fulfillment of the requirements for the degree of Masters of Science 
in Dentistry at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2014 
 
Director: Patrice B. Wunsch, D.D.S., M.S. 
Department of Pediatric Dentistry 
 
Purpose: The purpose of this study was to test whether children who have undergone cancer 
chemotherapy have a higher prevalence of enamel abnormalities of the second mandibular 
premolars than age matched controls. 
 
Methods: This study was a case-control design where the case group involved 26 subjects that 
had received chemotherapy treatment between the ages of 2 to 6 and at the time of the study 
were between the ages of 9 to 18.  The control group consisted of 26 subjects matched for age 
and sex to the case group that had not received chemotherapy. 
 The second mandibular premolars were assessed based on the types of defects, their 
number and location according to a modified DDE index. A secondary examiner, blinded to the 
  
 
 
results of the primary, analyzed photographs taken at examination and provided their own 
assessment in order to calibrate results. 
 
Result: Nominally there were more normal surfaces in the case group than in the control group 
(81% vs 70%) and fewer hypoplasias in the case group (5% vs 13%).  There was no statistical 
difference between the buccal and occlusal surfaces.  For the buccal surfaces, the cases were 
nominally lower but not statistically significant (P=0.0680) and there is no evidence for a case-
control difference on the lingual surfaces (P>0.9). 
 
Conclusions: In this study developmental defects of the enamel organ were not observed to be 
statistically different between the case and control groups, although previous studies have shown 
otherwise. 
1 
 
 
 
 
 
 
Introduction 
Today the number of children surviving cancer is increasing exponentially. With that said, 
clinicians are becoming more aware of the possible long term side effects and sequelae of 
cytotoxic chemotherapy. 1 2 Damage to the dentition is one such concern; since the developing 
teeth are sensitive to systemic disturbances. These are likely to produce a physiological function 
disturbance in the dentition that may cause ameloblasts to form enamel abnormally. 1 
 Chemotherapy is selectively toxic to active proliferating cells by interfering with DNA 
synthesis and replication, RNA transcription and cytoplasmic transport mechanisms. 
Chemotherapy interferes with the cell cycle and with intracellular metabolism, and therefore lead 
to dental abnormalities. 3 With respect to the effects of antineoplastic therapy in dental 
development it should be noted that children that received chemotherapy during the early years 
of their lives, a period associated with the development of teeth, presented with disturbances in 
the formation of enamel. 4 
 The immediate effects of chemotherapy and radiotherapy in soft and hard tissues are well 
documented, but less is known about the effects of chemotherapy itself in developing dental 
tissues. Animal studies have shown that chemotherapeutic agents induce qualitative and 
quantitative changes in dental tissues and odontogenesis, as well as inhibition of eruption. The 
extent of these abnormalities depends on factors such as the type of chemotherapeutic agent 
used, half-life of the agent and the number of cells in susceptible phases of the cell cycle. 5 
Enamel is the hardest substance in the human body and due to its high mineral content 
and organized structure, enamel has exceptional functional properties. We know that mature 
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enamel is mainly composed of carbonated hydroxyapatite which is made up of long and narrow 
crystals, packed into parallel arrays called enamel rods. The extracellular enamel matrix proteins 
secreted by the ameloblasts during amelogenesis suggest that this orchestrated extracellular 
process regulates nucleation, growth and organization of forming mineral crystals. 6 However, 
the process is not completely understood because the organic matrix does not persist when 
enamel is mineralized. 6 7 
 Dental enamel is elaborated by ameloblasts. As it is being formed this structure is highly 
hydrated with organic matrix and a low concentration of inorganic-apatite. Prior to the eruption 
of the tooth, this extracellular organic matrix undergoes numerous changes resulting in an 
increase of the inorganic phase and withdrawal of the organic structure and water. 6 7 
 This meticulous process is what we call “enamel maturation”, mineralization or 
calcification where the organic structure of the enamel is removed during early stages of 
mineralization and replaced by an increasing amount of mineral content. Subsequently, water 
decreases, resulting in a further increase of enamel density which is associated with progressive 
hardening of the enamel structure from very soft to very hard. 8  
 More recent studies have suggested that human enamel is formed in two distinct stages. 
In the first “secretory stage”, the long thin ribbon of enamel is formed immediately as the 
ameloblasts lay down enamel matrix proteins. 9 In this stage, the mineral phase of secretory 
enamel is approximately 10 to 20% of the volume, with the remaining portion occupied by 
matrix protein and water. When the thickness of the enamel and elongation of the crystals are 
established we pass into the second stage known as the “maturation stage”. 6 This coincides with 
the almost complete removal of enamel proteins by proteases and a rapid increase in mineral 
concentration suggesting that this second stage initiates upon completion of the enamel matrix. 
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The mineralization advances from the earliest formed matrix at the cuspal portion of the enamel 
dentin junction peripherally and cervically in a pattern approximating the incremental deposition 
of enamel matrix. 7  
 Up to this date, evidence suggests that this formation process is a protein-protein and 
protein-mineral interaction, having amelogenin as the predominant enamel matrix protein. These 
proteins are highly hydrophobic, rich in proline, glutamine, leucine and histidine. Although 
amelogenin is processed by proteinases shortly after its secretion, the intact full molecule is 
found exclusively in the region of the newly formed enamel. 9  
 Enamelin and ameloblastin may also have relevant importance in the enamel formation. 
Enamelin is a hydrophilic and acidic protein, rich in glycine, aspartic acid and serine. Like 
amelogenin, enamelin undergoes gradual enzymatic degradation extracellularly, suggesting that 
various degradation products of enamelin have different roles in amelogenesis. 6 The latter, was 
suggested to play a role in crystal growth based on its location relative to the Tomes process 
which is the secretory end of ameloblast and the site of crystal growth initiation. It has also been 
proposed that ameloblastin may also be a cell adhesion molecule that facilitates the attachment of 
the ameloblasts to the enamel matrix. 6 This factor may be essential for the maintenance of the 
ameloblasts in their differentiated state, which is ultimately required for proper enamel 
deposition. 10 
 During enamel formation, ameloblasts are susceptible to local trauma, hereditary 
conditions and systemic metabolic disturbances.  These disturbances may be reflected in the fully 
formed enamel as hypoplasia, hypocalcification or accentuated incremental lines.  All 
consequential effects depend on the intensity, duration of the etiologic factor and when the 
derangement occurs during crown formation. 11 Hypoplasia which is caused by local factors or 
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trauma will affect only one tooth and sometimes the adjacent tooth, whereas hereditary defects 
will begin at birth and affect the entire tooth crown. 8 Enamel hypoplasia is caused by a 
disturbance in the ameloblasts during tooth formation expressed by alterations of ameloblastic 
reproduction, secretory function, membrane permeability and calcium exchange across the cell 
membrane. Hence, the tooth enamel often acts as a repository of information on the systemic 
damage received during development. 12 These alterations are significantly more common in 
children surviving cancer. Children who had been treated for Acute Lymphoblastic Leukemia 
seem to be more severely affected and this may be reflected in the longer duration of therapy 
leading to a greater risk of affecting ameloblasts. 3  
 Among the drugs used for cancer treatment Vincristine (VCR) and Vinblastine (VBL) are 
widely used as anti-tumor agents. Biochemical and ultra-structural studies have shown that these 
drugs interact with tubulin molecules. 13 These are complex protein subunits of microtubules, and 
in some cell types the alkaloids cause them to aggregate into a large cytoplasmatic crystalloid 
structure. As a result, cellular function dependent on the microtubules suffers and cells in mitosis 
are irreversibly stopped in metaphase which can result in an abnormal appearance of the enamel. 
14 Some of the changes and effects are a combination of the interaction with the microtubules, 
inhibition of collagen and general protein, increased autophagic activity as well as necrotic 
changes. 13 
Previous studies on effects of VCR on dentinogenesis indicated that this drug has immediate, 
varied and dose-dependent effects on several stages in the process.  In some cases, VCR 
produced an accumulation of numerous abnormal metaphases of pre-odontoblasts in the apical 
part of the pulp near the terminal odontogenic epithelium. Other cases showed that metaphases 
were not observed among fully developed odontoblasts and therefore they lost their capacity to 
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proliferate. 13 The results showed that VCR effects differed across regions of the tooth. The 
number and disposition of odontoblasts was reduced in all areas of tooth sections, especially in 
the pulp horn. In the central part of coronal and radicular pulp tissue blood vessels were dilated 
and filled with blood cells. The histologic appearance of newly formed dentine was irregular. 15 
 Doxorubicin is a drug widely used as an antineoplastic agent that damages DNA. This 
drug is used to treat many cancers in children. Due to recent advances in cancer treatment, there 
is a growing population of young patients with long-term side-effects from chemotherapy 
including abnormalities of the dentition, which may occur in teeth undergoing odontogenesis 
during treatment. 16 The effects of continuous exposure to therapeutic concentrations of 
doxorubicin are undetermined. All dilutions of doxorubicin significantly inhibited fibroblast cell 
proliferation. The dental pulp itself is a loose connective tissue containing various 
subpopulations of cells, including fibroblasts and undifferentiated cells capable of transformation 
into mineralized tissue. In addition, doxorubicin has been reported to produce dentinal 
hypoplasia in humans. 16  
 Considering that tooth enamel can be affected by adverse biological events, the changes 
in structure can provide clues to the time and nature of these events. Therefore, enamel defects 
can then be studied as a marker of many adverse biological events that occurred during their 
developmental phase, and that may have applications in clinical and epidemiological 
investigations. 17 Improving knowledge and understanding of these effects would make it 
possible to improve clinical management, educate parents that normal dental structures may be 
affected and offer a list of solutions to mitigate any impact. 2 
 Thus, the aim of the study was to establish a positive correlation between chemotherapy 
and enamel abnormalities of the second mandibular premolars in the pediatric population that 
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received chemotherapy treatment from two to four years of age. The reason we focused on the 
second mandibular premolars is because the enamel for the second mandibular premolars forms 
between the ages of two to six – which is when the case subject population had received 
chemotherapy treatment. If the findings are positive then the results will make it possible to: 
 Provide proof that in the Pediatric Dental community, there is a positive correlation 
between chemotherapy and alterations in the enamel formation.  This will help determine 
the best approaches to help patients who may develop dental issues due to defective tooth 
enamel. 
 Educate parents of children that will be receiving chemotherapy that normal dental 
structures may be affected and offer a list of solutions to resolve such issues. 
 Educate parents of children that have received chemotherapy in the past that normal 
dental structures may have been affected by the procedure while also offering a list of 
solutions to mitigate any impact. 
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Methods 
Study Design 
This study was approved by the VCU Institutional Review Board (IRB).  Approval #: HM15036. 
This study utilized a case-control design where the case group involved subjects that had 
received chemotherapy treatment between the ages of 2 to 6. At the time of the study, subjects 
were between the ages of 9 to 18, which is when the mandibular second premolars should be 
fully erupted. 
 The case group was accessed from the Long-term Survivor Clinic located at St. Mary’s 
Hospital, which is part of the Pediatric Hematology and Oncology division of the Virginia 
Commonwealth University Health Systems. The subjects were addressed during their follow-up 
appointments with a script presenting the purpose of the study.  
 The control group consisted of up to 69 subjects matched for age and sex to the case 
group and were accessed randomly through the Pediatric Dental Clinic at Virginia 
Commonwealth University, School of Dentistry (VCU). They were addressed during their six 
months periodical examinations with a script presenting the purpose of the study. 
 The following exclusion criteria applied to all subjects: 
 Previous trauma in the premolar area 
 Diagnosed with hereditary conditions or syndromes 
 Received endodontic treatment in the second mandibular premolar 
 Received or currently in orthodontic treatment 
 Teeth that are partially erupted 
 Not living in a fluoridated water community 
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Data Collection 
Informed consent was obtained from parents of those participating in the study. Parents 
completed a questionnaire about the subject’s health history. Subjects were examined in a semi 
supine position. Intraoral examination with a disposable dental mirror was performed on all 
surfaces of the second mandibular premolar. Teeth were examined without previous prophylaxis, 
but debris was removed from the individual sites, where visibility was compromised, by using 
4x4 gauze. This assessment was based on the types of defects, their number and location.  The 
type and the location of the developmental defects of the enamel were classified according to the 
modified DDE index introduced by Clarkson and O’ Mullane. 18 
 After examination, the second mandibular premolar was photographed using a Canon 2Ti 
camera with a 90mm Tamron portrait lens at a reduction of 1:32 with a Dine Corp. ring flash or 
point flash. The buccal, lingual and occlusal surfaces of #20 and #29 were photographed directly. 
Photos were taken in order for the secondary examiner to analyze enamel defects and provide 
their own numerical value according to the same modified DDE index used by the primary 
examiner.  This was done in order to calibrate results. 
 
Classification of Developmental defects 
For the purpose of the study, the type and location of the developmental defects of enamel were 
classified according to the modified DDE index (Table 1). 18 
 
Statistical Methods 
To compare the ages in the cases and controls, a test of equivalence was used. The cases and 
controls were compared using a likelihood-ratio chi-square test or a t-test, as appropriate. The 
9 
 
 
 
cancer, leukemia, and control patients are compared using Wilcoxon’s rank sum test. The test of 
the specific aim was accomplished using two analyses: Considering DDE as a binary outcome, a 
repeated-measures logistic regression included the following factors in the model: Case versus 
control, sex, age, tooth, and surface. Considering DDE as a numerically scored value (0 to 3), a 
repeated-measures mixed-model ANOVA included the same factors in the model plus it 
considered that the group differences may vary by surface. All analyses were performed using 
SAS software (SAS version 9.3, JMP version 10.0, SAS Institute Inc., Cary NC). 
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Results 
First, the results of screening and patient recruitment are described. Then the demographic, 
medical and dental characteristics of the cases and controls are compared. The primary analyses 
describe the differences in developmental defects of the enamel in the main section. And finally, 
the cases are divided into those with cancer and those with leukemia and these are compared to 
controls. 
 
Patient recruitment 
The clinic had on record 456 children that were between the ages of 9 to 18. Of these, 95 
received chemotherapy between the ages of 2 to 6. Of the 95, 19 have died, 6 have moved away 
and are no longer followed by the clinic, and 1 had relapsed and is back on treatment.  This left 
69 prospective cases between the ages of 9 to 18 that received treatment between the ages of 2 to 
6. Of the 69 potential subject cases, 26 were eventually recruited for the study. 43 subjects were 
excluded due to one or more of the following reasons: 
 Diagnosed with hereditary conditions or syndromes 
 Received endodontic treatment in the second mandibular premolar 
 Received or currently in orthodontic treatment 
 Teeth that were partially erupted 
 Scheduling constraints – note: this was the primary reason for exclusion, and the 
primary source of potential bias 
 The 26 cases were diagnosed most commonly as ALL (42%, n=11) and next most 
commonly with Wilm’s tumor (19%, n=5). Additionally there were 6 cases of ALL, and one 
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each of the following: AML, anaplastic large cell lymphoma, brain tumor, and non-Hodgkins 
lymphoma. The chemotherapy protocols for these cases are listed in Appendix 3. 
 To obtain the 26, sex and age matched, controls we used patients presenting to the VCU 
Pediatric Dental Clinic for routine checkups.  The researcher looked at the day’s schedule for sex 
and age matched control subjects to previously examined case subjects.  By the end of the study, 
in order to meet time constraints, one more male case subject and one fewer female subject was 
examined.  This was due to scheduling constraints with a goal to match age over sex. 
 In the case group there were 11 males and in the control group there were 12 males 
(Table 2). In the case group the average age was 12.8 years (SD=2.6) and in the control group 
the average age was 13.3 years (SD=2.5) and the two ages were equivalent to within one year (P 
= 0.2388).  
 
Description of Subjects 
Overall, 56% were males and the average age of the cases and controls was 13 (SD=2.5, range = 
9 to 18). The most common race category was African American (60%), followed by Caucasian 
(37%). Additionally, there was one Asian and one “other.” Hispanics comprised 8% (n=4). The 
cases were more likely to have been hospitalized for a prolonged fever episode (31% vs. 
8%, P=0.0299) but no more likely to report a latex allergy (4% overall, P=0.0912) or other 
allergies (17% overall, P=0.2676). 
 Only one control patient reported any serious problems associated with any previous 
dental treatment. There was no difference between the cases and controls on whether they had 
always had fluoride in their water (85% vs 88%, P>0.6), the number of dental exams per year 
(mean = 1.7 vs 1.7, P=1), whether they always used tooth paste with fluoride (92% vs 92%, 
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P=1), whether they used a fluoride mouth rinse (38% vs 35%, P>0.7), whether they flossed (69% 
vs 46%, P = 0.0905), or whether they had jaw clicking, etc. (8% vs 8%, P=1). All cases and 
controls reported that they brushed their teeth but the case group reported brushing their teeth 
more often (mean = 2.03 vs 1.61 per day, P=0.045). Both groups reported snacking between 
meals. 
 
Developmental defects of the enamel  
The primary outcome was the number of developmental defects in the enamel on the buccal, 
lingual and occlusal surfaces of #20 and #29. The DDE ratings were compared between the 
primary rater and the secondary rater to assess agreement. When the secondary rater examined 
the photographs he discovered the lingual surface could be not be accurately accessed via the 
photographs.  Since the secondary rater could not assess the lingual surface, these scores were 
not included in the assessment of agreement.  
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Table 3 shows that there were a total of only 13 discrepancies out of 206 surfaces compared. The 
two raters agreed 94% of the time and the Kappa agreement was statistically significant (88%, 
P<.0001). 
 The DDE for each tooth and surface is summarized in Table 4. As may be seen, there is 
no difference between the teeth and so Table 5 summarizes the results by surface. As may be 
seen, the lingual surface has fewer abnormalities than either the buccal or occlusal surfaces. 
Analysis showed that the Buccal and Occlusal surfaces had statistically similar results.  Table 6 
depicts this analysis in that nominally there are more normal Buccal and Occlusal surfaces in the 
case group (73%) vs. the controls (59%).  Hypoplasias were nominally higher in the control 
group (7%) vs. the cases (1%). 
 The primary comparison is between the cases and controls and the summary of these 
results appears in 7. Note that nominally there are more normal surfaces in the cases than in the 
controls (80% vs 70%) and that there are nominally fewer hypoplasias in the cases (5% vs 13%). 
Two analyses were considered, the first considered DDE as a binary outcome (normal vs 
abnormal) and the second considers DDE as a numeric score ranging from 0=normal to 
3=hypoplasia. In the case of DDE as a binary outcome, a repeated-measures logistic regression 
included the following factors in the model: Case versus control, sex, age, tooth, and surface. 
There was no differences due to sex (P>0.4), age (P>0.2) or between the cases and controls 
(P=0.4517). There was no difference between the two teeth (P>0.5) but there was a difference 
between the three surfaces (P=0.0002). Tukey’s multiple comparison procedure indicated that 
the probability of a defect on the lingual surface (6.6%) was lower than the probability of a 
defect on the buccal or occlusal surfaces (34.3% and 35.4%, respectively). There was no 
difference between the buccal and occlusal surfaces. 
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 Considering DDE as a numerically scored value (0 to 3), a repeated-measures mixed-
model ANOVA included the same factors in the model plus it considered that the group 
differences may vary by surface. The results indicated that there was a sex difference 
(P=0.0322). Females had a higher mean of 0.79 (95% CI = 0.47 to 1.10) than did the male mean 
of 0.32 (95% CI = 0.04 to 0.60). There was no age difference (P=0.122) and again there was 
difference in DDE depending upon the surface (P<.0001). Although there was no overall group 
difference (P=0.2356), the size of the group difference did depend upon the surface (P=0.0178).  
shows the estimated mean for each group and surface. For the buccal surfaces, the cases were 
nominally lower (P=0.0680) and there is no evidence for a case-control difference on the lingual 
surfaces (P>0.9). 
 
Cancers and Leukemia 
In this section, we describe the defects in two groups of cases. The two case groups are those 
with cancers (Wilm’s tumor, brain tumor, anaplastic large cell lymphoma) and those with 
leukemia (ALL of all types, and AML). Table 9 describes the number of teeth with each of the 
conditions listed for the cancer cases, the leukemia cases, and the controls. Wilcoxon’s 
nonparametric test indicated that the three groups were not significantly different on any of the 
variables (P>0.05). 
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Discussion 
Previous studies 19 5 20 21 have proven that chemotherapeutic agents used to treat childhood 
cancers resulted in a higher prevalence of various developmental defects in teeth because they 
were used during a period of time associated with the development of teeth.  In this study we 
were attempting to confirm this by focusing on enamel developmental defects. 
 We were able to eliminate the majority of potential confounders prior to examination and 
the most common reasons for not participating in the study were scheduling availability, past 
orthodontic treatment, root canal treatment, and previous trauma to the area.  Even though three 
subjects noted they did not live in a fluoridated water community they were included due to the 
fact that they were using fluoridated tooth paste and also due to the halo effect. 
 The number of participants were age and gender matched in most cases except for one 
more male in the case group and one more female in the control group.  This was due to time 
constraints for this study in concert with scheduling constraints of subjects.  The primary goal 
was to match on age over gender. 
 Initial analysis showed that the case group presented with more demarcated opacities than 
the control group, and the control group presenting with more diffuse opacities and hypoplasia 
than the case group.  However, there were no statistically significant differences between the two 
groups.  Thus the initial hypothesis appears to have not been confirmed, however the results are 
inconclusive due to one or more of the reasons noted below.  In any case control study with 
negative results, there are four explanations for the findings. 
 
1. There is no difference between the two groups.  In the end both case and control groups 
showed statistically similar results when it comes to enamel formation. This may be due 
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to the fact that multiple chemotherapeutic protocols were used to treat case subjects.  It is 
possible that the volume and/or type of chemotherapeutic agent used to treat the cancers 
may have different effects on enamel formation.  This study did not take this into 
account. 
2. Insufficient sample size and power to document a difference.  Though there was a goal to 
include more case subjects in the study however, there were exclusion criteria and 
scheduling constraints that had to be met.  This may have presented a bias in the data 
collection that may have been reduced had the subject populations been larger. 
3. There was a bias in the case subject collection methods.  Only those subjects that were 
able to make their appointments, and passed the exclusion criteria, were recruited. For 
example, subjects that presented with any syndromes were excluded. This may have 
excluded subjects that were exposed to different systemic or environmental factors, 
which may have resulted in an alternative conclusion. 
4. There was a bias in the control subject collection methods.  Only those subjects that were 
available and present at a dental examination were included in the control group. It is 
possible the results may have been different had the control subjects come from a more 
non-specific control population. 
 
 It should be noted that the lack of finding a difference between the case and control 
populations does not prove there is no difference.  This study has simply not shown a difference 
between the two study groups.  Further research is warranted. Given the reasons above, future 
studies should include a larger case subject population, use a longer period of data collection, 
and cover a larger population of control patients – for example, ones collected not only at dental 
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checkup exams.  Additionally, future studies should consider using less exclusion criteria since 
this limited the available study population. A study whereby cases were identified prospectively 
while they were in the hospital for treatment could have fewer subjects excluded. 
 One aspect of the statistical analysis that was found to be statistically significant was in 
the realm of oral hygiene.  All groups reported brushing their teeth but the case group reported 
brushing their teeth more often (mean = 2.03 vs 1.61 per day, P=0.045). While the control group 
did present more diffuse opacities, statistical analysis shows a non-significant difference between 
the two groups.  With that said, it is likely that a larger study would have proved that an 
inadequate frequency of oral hygiene habits can cause diffuse opacities associated with 
decalcified areas.  However, one may conclude that oral hygiene habits have a more significant 
impact on enamel formation than the effects of chemotherapeutic agents. 
 The general consideration concerning the etiology of opacities is that tooth 
morphogenesis is affected due to a harmful exposure during its mineralization phase.  The fact 
that case group subjects present 81% normal enamel may imply that the regimen or protocols of 
chemotherapy are strong enough to eradicate the disease but are not harmful to secondary 
structures such as tooth enamel.  However, future studies against larger populations may prove 
otherwise. 
Though previous studies have shown a higher prevalence of development defects of the 
enamel organ in patients treated with chemotherapeutic agents, in this study these abnormalities 
were not observed to be statistically different than a control population.  However, its possible 
study methods may have presented bias into the results. 
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Conclusion 
In this study we were attempting to prove the hypothesis that chemotherapeutic agents used to 
treat different forms of cancer can cause developmental defects during enamel formation.  This 
study did not observe that enamel was statistically effected differently between the case and 
control groups; although previous studies have shown otherwise.  However, it is possible study 
methods may have presented bias into the results. 
 It should be noted that the lack of finding a difference between the case and control 
populations does not prove there is not a difference between the two groups.  This study has 
simply not shown a statistical difference between the two specific study groups.  Further 
research, against a larger study population, may prove otherwise. 
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Tables 
Table 1 Modified DDE Index 
Code 
Type of 
defect Definition 
0 Normal  
1 Demarcated 
opacities 
The demarcated opacity presents a normal thickness of enamel 
with a surface intact, but there is a change in the translucency of 
enamel, of varying degree. This translucency is demarcated from 
the adjacent normal enamel with crisp and clear limits, and may 
present a white, beige, yellow or brown.17 
2 Diffuse 
opacities 
Diffuse opacity is also an abnormality involving a change in the 
translucency of enamel, of varying degree, and variable coloration 
as demarcated opacity. However, there is no clear boundary 
between adjacent normal enamel and diffuse opacity, and may 
present clinically in linear form or on plates, or have a confluent 
distribution.17 
3 Hypoplasia Hypoplasia is defined as quantitative defect of enamel visually and 
morphologically identified as involving the surface of enamel (an 
external defect) and associated with reduced thickness of enamel. 
The defective enamel may occur as (a) shallow or deep pits 
arranged horizontally in a linear fashion across the tooth surface or 
generally distributed over the whole or part of the enamel surface; 
(b) the defective enamel may occur as small or large, wide or 
narrow grooves; (c) in some instances there may be partial or 
complete absence of enamel over small or considerable areas of 
dentine.12 
4 Other defects If any defect does not fall into these categories, they were scored 
as others. 
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Table 2 Case-Control Matching 
 Count 
Age Case Control 
 Females 
9 2 0 
10 2 2 
11 1 0 
12 0 1 
13 4 3 
14 1 1 
15 1 2 
16 0 1 
17 0 2 
 Males 
9 1 1 
10 1 2 
11 1 1 
12 3 2 
13 1 2 
14 3 3 
15 1 1 
16 1 0 
17 2 1 
18 1 1 
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Table 3 Agreement between the primary and secondary examiner on the DDE index 
 Primary Rater  
Secondary Rater Normal 
Demarcated 
opacities 
Diffuse 
opacities Hypoplasia Total 
Normal 133 7 0 0 140 
Demarcated opacities 0 16 4 0 20 
Diffuse opacities 0 0 17 0 17 
Hypoplasia 2 0 0 27 29 
  135 23 21 27 206 
Exact agreement = 94%, Chance corrected Kappa agreement = 88%, P<.0001. 
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Table 4 DDE for each tooth location by cases and controls 
  Cases  Controls 
Location DDE % (n)   % (n) 
20 Buccal Normal 77 (20)  58 (15) 
  Demarcated opacities 8 (2)  4 (1) 
  Diffuse opacities 8 (2)  23 (6) 
  Hypoplasia 8 (2)  15 (4) 
20 Lingual Normal 92 (24)  92 (24) 
  Demarcated opacities 4 (1)  0 (0) 
  Diffuse opacities 4 (1)  8 (2) 
 Hypoplasia 0   0  
20 Occlusal Normal 73 (19)  58 (15) 
  Demarcated opacities 15 (4)  12 (3) 
  Diffuse opacities 4 (1)  12 (3) 
  Hypoplasia 8 (2)  19 (5) 
29 Buccal Normal 72 (18)  58 (15) 
  Demarcated opacities 16 (4)  4 (1) 
  Diffuse opacities 4 (1)  19 (5) 
  Hypoplasia 8 (2)  19 (5) 
29 Lingual Normal 96 (24)  92 (24) 
  Demarcated opacities 4 (1)  0 (0) 
  Diffuse opacities 0 (0)  8 (2) 
 Hypoplasia 0   0  
29 Occlusal Normal 68 (17)  62 (16) 
  Demarcated opacities 20 (5)  12 (3) 
  Diffuse opacities 8 (2)  4 (1) 
  Hypoplasia 4 (1)   23 (6) 
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Table 5 DDE for each surface by cases and controls 
  Cases  Controls 
Surface DDE % (n)   % (n) 
Buccal Normal 75 (38)  58 (30) 
  
Demarcated 
opacities 12 (6)  4 (2) 
  Diffuse opacities 6 (3)  21 (11) 
  Hypoplasia 8 (4)  17 (9) 
Lingual Normal 94 (48)  92 (48) 
  
Demarcated 
opacities 4 (2)  0 (0) 
  Diffuse opacities 2 (1)  8 (4) 
 Hypoplasia 0   0  
Occlusal Normal 71 (36)  60 (31) 
  
Demarcated 
opacities 18 (9)  12 (6) 
  Diffuse opacities 6 (3)  8 (4) 
  Hypoplasia 6 (3)   21 (11) 
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Table 6 Percentage of Surfaces Affected 
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Table 7 DDE by cases and controls 
 Cases  Controls 
DDE % (n)   % (n) 
Normal 80 (122)  70 (109) 
Demarcated 
opacities 11 (17)  5 (8) 
Diffuse opacities 5 (7)  12 (19) 
Hypoplasia 5 (7)   13 (20) 
 
 
 
Table 8 DDE scores by cases and controls 
 
DDE  
Surface Estimated Mean 95% CI P-value1 
 Cases  
Buccal 0.561 0.239 0.883 0.0680 
Lingual 0.169 -0.153 0.490 0.9533 
Occlusal 0.561 0.239 0.883 0.1347 
 Controls  
Buccal 0.982 0.663 1.301  
Lingual 0.155 -0.164 0.474  
Occlusal 0.905 0.586 1.224   
1 The cases and controls were not significantly different by repeated-measures ANOVA (P>0.2) 
but the group difference varied by surface (P=0.0178). P-value compares the case and controls 
separately by each surface. 
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Table 9 Counting teeth by cancer, leukemia, and controls 
 Cancer  Leukemia  Controls  
Number of teeth with 
… % (n)   % (n)  % (n) 
P-
value 
all surfaces normal         0.1980 
0 38 (3)  17 (3)  42 (11)  
1 38 (3)  17 (3)  4 (1)  
2 25 (2)   67 (12)   54 (14)   
demarcated opacities            0.2562 
0 50 (4)  72 (13)  81 (21)  
1 25 (2)  17 (3)  8 (2)  
2 25 (2)   11 (2)   12 (3)   
diffuse opacities            0.0539 
0 63 (5)  94 (17)  62 (16)  
1 38 (3)  0 (0)  15 (4)  
2 0 (0)   6 (1)   23 (6)   
hypoplasia            0.1625 
0 75 (6)  94 (17)  73 (19)  
1 13 (1)  6 (1)  4 (1)  
2 13 (1)   0 (0)   23 (6)   
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Appendix 1: Health History Form 
 
Comparing tooth enamel disturbances in a pediatric population that received chemotherapy treatment to 
age-matched controls from the VCU Pediatric Dentistry clinic. 
HEALTH HISTORY FORM 
 
Patient’s Name     Date of Birth  Sex   Race 
IN THIS HEALTH HISTORY FORM, “YOU” ALWAYS REFERS TO THE RESEARCH PARTICIPANT. IF YOU ARE A LEGALLY 
AUTHORIZED REPRESENTATIVE, PLEASE REMEMBER THAT “YOU” REFERS TO THE STUDY PARTICIPANT. Answer all questions 
by circling Yes (Y) or No (N) All responses are kept confidential 
 
Medical and Dental History 
Question Answer Description 
Have you ever been diagnosed with any 
disease by a medical professional? If 
yes, describe condition and any 
treatments received.  Please list all 
diseases if more than one.  Also list date 
or year of diagnosis. 
Y    N 
 
Have you ever been hospitalized for a 
prolonged fever episode? If yes, please 
describe and indicate if treated with 
antibiotics 
 
Y    N 
 
Are you Allergic to or have you had any 
adverse reactions to: 
 
 
     Latex or Rubber Products? Y    N  
     Other allergies or reactions?  Please, 
list. 
Y    N 
 
Have you had any serious problems 
associated with any previous dental 
treatment? 
Y    N 
 
Have you always have fluoride in your 
water? 
Y    N 
 
How often do you get periodical dental 
exams? 
 
 
Have you always used fluoridated tooth 
paste? 
Y    N 
 
Do you use any fluoride mouth rinse? Y    N  
Do you brush your teeth? How often? Y    N  
Do you floss your teeth? How often? Y    N  
Have you had any injuries or trauma to 
your teeth? 
Y    N 
 
Have you had braces? Y    N  
Have you had a root canal done? Y    N  
Do you have clicking or popping of jaw 
joint, pain near ear, difficulty opening 
mouth, grind or clench teeth? If yes, 
please describe. 
Y    N 
 
Do you snack between meals?  If yes, 
please   describe typical snacks. 
Y    N 
 
 
I understand the importance of a truthful Health History to assist the doctor in this research.  I have had the opportunity to discuss my 
Heath History with my doctor. 
 
      
Date Signature of Person Completing Health History  Doctor’s Initials 
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Appendix 2: Chemotherapy protocols for the cases 
 
Diagnosis Chemotherapy protocol N 
ALL 8CUSTOM 1 
ALL AALL0331 5 
ALL POG 9605 1 
ALL POG 9905 1 
ALL POG 9905 Regimen A 1 
ALL POG9605 1 
ALL POG9605,AALL0232,AALL0031 1 
AML POG 9822 1 
Anaplastic Large Cell Lymphoma (Murphy's Stage 
III) 
POG 9315 1 
B-lineage ALL AALL0331 1 
B-lineage ALL POG 9605 1 
Brain Tumor POG 9233 1 
Non Hogkins Lymphoma POG 9605 1 
Pre B ALL AALL0331 2 
Pre B ALL PCP 1991 1 
Pre B ALL POG 9904 Regimen D 1 
Wilm's Tumor DD4A 3 
Wilm's Tumor EE4A 2 
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